 Daniel LaBarbera
Concepts (292)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA-Binding Proteins | 6 | 2023 | 1318 | 2.130 |
Why?
| | Antineoplastic Agents | 11 | 2022 | 1879 | 1.680 |
Why?
| | Spheroids, Cellular | 4 | 2020 | 57 | 1.670 |
Why?
| | DNA Helicases | 3 | 2023 | 133 | 1.590 |
Why?
| | Aldehyde Reductase | 7 | 2018 | 24 | 1.480 |
Why?
| | Drug Discovery | 7 | 2022 | 124 | 1.420 |
Why?
| | Neoplasms | 5 | 2023 | 2106 | 1.410 |
Why?
| | Epithelial-Mesenchymal Transition | 5 | 2021 | 167 | 1.390 |
Why?
| | Drug Screening Assays, Antitumor | 8 | 2020 | 180 | 1.320 |
Why?
| | DNA Topoisomerases, Type II | 5 | 2019 | 44 | 1.220 |
Why?
| | Topoisomerase II Inhibitors | 3 | 2019 | 23 | 1.220 |
Why?
| | Acridines | 3 | 2014 | 7 | 1.180 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 752 | 1.150 |
Why?
| | Cell Line, Tumor | 19 | 2022 | 2716 | 1.060 |
Why?
| | Urinary Bladder Neoplasms | 3 | 2022 | 196 | 1.020 |
Why?
| | Hydrolyzable Tannins | 4 | 2014 | 5 | 1.000 |
Why?
| | Antigens, Neoplasm | 3 | 2016 | 222 | 0.930 |
Why?
| | Colorectal Neoplasms | 2 | 2020 | 617 | 0.870 |
Why?
| | Plant Extracts | 2 | 2017 | 154 | 0.870 |
Why?
| | TCF Transcription Factors | 2 | 2020 | 20 | 0.870 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 67 | 0.840 |
Why?
| | High-Throughput Screening Assays | 5 | 2020 | 123 | 0.830 |
Why?
| | Small Molecule Libraries | 4 | 2020 | 80 | 0.770 |
Why?
| | Cell Plasticity | 1 | 2021 | 23 | 0.730 |
Why?
| | Imidazoles | 5 | 2021 | 209 | 0.730 |
Why?
| | Clonal Evolution | 1 | 2020 | 27 | 0.690 |
Why?
| | Neoplasm Proteins | 2 | 2020 | 385 | 0.680 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 344 | 0.670 |
Why?
| | Histones | 1 | 2023 | 535 | 0.630 |
Why?
| | Naegleria fowleri | 1 | 2017 | 1 | 0.590 |
Why?
| | Larrea | 1 | 2017 | 1 | 0.590 |
Why?
| | Entamoeba histolytica | 1 | 2017 | 7 | 0.590 |
Why?
| | Antiprotozoal Agents | 1 | 2017 | 12 | 0.590 |
Why?
| | Giardia lamblia | 1 | 2017 | 21 | 0.580 |
Why?
| | Drug Design | 5 | 2022 | 151 | 0.570 |
Why?
| | Neoplastic Stem Cells | 4 | 2020 | 333 | 0.560 |
Why?
| | Transcription Factor 7-Like 2 Protein | 1 | 2016 | 24 | 0.530 |
Why?
| | Imaging, Three-Dimensional | 2 | 2017 | 538 | 0.500 |
Why?
| | Adenosine Triphosphate | 3 | 2019 | 431 | 0.490 |
Why?
| | Colonic Neoplasms | 2 | 2016 | 222 | 0.480 |
Why?
| | Hepatocytes | 1 | 2015 | 196 | 0.480 |
Why?
| | Porifera | 3 | 2009 | 8 | 0.470 |
Why?
| | Breast Neoplasms | 4 | 2017 | 1865 | 0.460 |
Why?
| | beta Catenin | 1 | 2016 | 220 | 0.460 |
Why?
| | Amidines | 1 | 2013 | 16 | 0.450 |
Why?
| | Heterocyclic Compounds | 1 | 2013 | 18 | 0.450 |
Why?
| | Adenocarcinoma | 1 | 2020 | 795 | 0.450 |
Why?
| | Glycosides | 1 | 2013 | 33 | 0.440 |
Why?
| | Amides | 1 | 2013 | 88 | 0.430 |
Why?
| | Retinoids | 1 | 2012 | 31 | 0.410 |
Why?
| | Phyllanthus emblica | 1 | 2012 | 1 | 0.410 |
Why?
| | Apoptosis | 7 | 2021 | 2366 | 0.400 |
Why?
| | Humans | 38 | 2023 | 115049 | 0.380 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2015 | 698 | 0.380 |
Why?
| | Cell Survival | 5 | 2021 | 1022 | 0.380 |
Why?
| | Fruit | 1 | 2012 | 127 | 0.380 |
Why?
| | Gene Expression Regulation, Neoplastic | 6 | 2022 | 1145 | 0.370 |
Why?
| | Promoter Regions, Genetic | 7 | 2022 | 1133 | 0.360 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2011 | 95 | 0.360 |
Why?
| | Transcription, Genetic | 3 | 2021 | 1317 | 0.350 |
Why?
| | Mice | 14 | 2023 | 14928 | 0.350 |
Why?
| | Telomerase | 2 | 2022 | 206 | 0.340 |
Why?
| | Keratin-5 | 3 | 2017 | 46 | 0.340 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2021 | 637 | 0.340 |
Why?
| | Alkaloids | 1 | 2009 | 22 | 0.340 |
Why?
| | Models, Molecular | 6 | 2015 | 1379 | 0.310 |
Why?
| | Quinoxalines | 2 | 2007 | 60 | 0.310 |
Why?
| | Models, Biological | 3 | 2017 | 1636 | 0.310 |
Why?
| | Thyroid Carcinoma, Anaplastic | 2 | 2019 | 34 | 0.310 |
Why?
| | Caspases | 1 | 2009 | 245 | 0.300 |
Why?
| | Catalytic Domain | 2 | 2023 | 197 | 0.300 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2021 | 192 | 0.300 |
Why?
| | Cell Proliferation | 7 | 2021 | 2191 | 0.300 |
Why?
| | Animals | 18 | 2023 | 31868 | 0.290 |
Why?
| | Molecular Structure | 6 | 2016 | 438 | 0.290 |
Why?
| | Thyroid Neoplasms | 2 | 2021 | 263 | 0.280 |
Why?
| | Antibiotics, Antineoplastic | 2 | 2006 | 109 | 0.270 |
Why?
| | Receptors, Progesterone | 3 | 2017 | 319 | 0.230 |
Why?
| | Structure-Activity Relationship | 4 | 2019 | 503 | 0.230 |
Why?
| | Biomarkers, Tumor | 2 | 2022 | 1045 | 0.230 |
Why?
| | Oncogenes | 2 | 2022 | 104 | 0.230 |
Why?
| | Benzimidazoles | 1 | 2005 | 137 | 0.230 |
Why?
| | Poly ADP Ribosylation | 1 | 2023 | 8 | 0.230 |
Why?
| | Indoles | 1 | 2006 | 304 | 0.220 |
Why?
| | Progesterone | 3 | 2017 | 232 | 0.220 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2023 | 40 | 0.220 |
Why?
| | Integrins | 1 | 2022 | 79 | 0.200 |
Why?
| | Tripartite Motif-Containing Protein 28 | 1 | 2021 | 6 | 0.200 |
Why?
| | Neoplasm Metastasis | 2 | 2016 | 524 | 0.190 |
Why?
| | HEK293 Cells | 3 | 2012 | 590 | 0.180 |
Why?
| | DNA (Cytosine-5-)-Methyltransferase 1 | 1 | 2020 | 13 | 0.180 |
Why?
| | Carcinogenesis | 1 | 2022 | 178 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 146 | 0.180 |
Why?
| | Mutation | 5 | 2022 | 3350 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 164 | 0.180 |
Why?
| | RNA, Neoplasm | 1 | 2020 | 80 | 0.170 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2022 | 182 | 0.170 |
Why?
| | Glioblastoma | 1 | 2022 | 253 | 0.170 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 31 | 0.170 |
Why?
| | Organoids | 1 | 2020 | 74 | 0.170 |
Why?
| | Binding, Competitive | 1 | 2019 | 195 | 0.170 |
Why?
| | Cell Cycle | 2 | 2014 | 544 | 0.170 |
Why?
| | PTEN Phosphohydrolase | 1 | 2020 | 140 | 0.160 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 299 | 0.160 |
Why?
| | HIV Protease | 1 | 2019 | 3 | 0.160 |
Why?
| | Nuclear Proteins | 1 | 2023 | 593 | 0.160 |
Why?
| | Depsipeptides | 2 | 2011 | 13 | 0.160 |
Why?
| | Adenocarcinoma, Follicular | 1 | 2019 | 34 | 0.160 |
Why?
| | Vascular Remodeling | 1 | 2020 | 153 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 147 | 0.160 |
Why?
| | HIV Protease Inhibitors | 1 | 2019 | 64 | 0.160 |
Why?
| | Drug Resistance | 1 | 2019 | 158 | 0.150 |
Why?
| | alpha-Glucosidases | 1 | 2018 | 9 | 0.150 |
Why?
| | Solanum tuberosum | 1 | 2018 | 7 | 0.150 |
Why?
| | alpha-Amylases | 1 | 2018 | 16 | 0.150 |
Why?
| | Polyphenols | 1 | 2018 | 16 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 228 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 1 | 2020 | 814 | 0.150 |
Why?
| | DNA Damage | 1 | 2020 | 357 | 0.150 |
Why?
| | Masoprocol | 1 | 2017 | 3 | 0.150 |
Why?
| | Viral Nonstructural Proteins | 1 | 2018 | 54 | 0.150 |
Why?
| | Naphthols | 1 | 2017 | 7 | 0.150 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2017 | 11 | 0.150 |
Why?
| | Mice, Nude | 3 | 2021 | 631 | 0.140 |
Why?
| | Receptors, Retinoic Acid | 1 | 2017 | 50 | 0.140 |
Why?
| | Down Syndrome | 1 | 2022 | 335 | 0.140 |
Why?
| | Chikungunya virus | 1 | 2018 | 61 | 0.140 |
Why?
| | Transcriptome | 1 | 2022 | 726 | 0.140 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 179 | 0.140 |
Why?
| | Recombinant Proteins | 1 | 2020 | 1237 | 0.140 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 347 | 0.140 |
Why?
| | Emodin | 1 | 2016 | 3 | 0.140 |
Why?
| | Receptors, Estrogen | 3 | 2017 | 372 | 0.140 |
Why?
| | Biological Products | 2 | 2011 | 171 | 0.130 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2011 | 1857 | 0.130 |
Why?
| | Xanthines | 1 | 2015 | 15 | 0.130 |
Why?
| | Protein Interaction Maps | 1 | 2016 | 34 | 0.130 |
Why?
| | Marine Toxins | 1 | 2015 | 12 | 0.130 |
Why?
| | Tretinoin | 2 | 2017 | 124 | 0.130 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2016 | 128 | 0.130 |
Why?
| | Virus Replication | 1 | 2018 | 393 | 0.130 |
Why?
| | Sorbitol | 2 | 2012 | 15 | 0.130 |
Why?
| | Microglia | 2 | 2014 | 202 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 396 | 0.130 |
Why?
| | Progestins | 2 | 2012 | 75 | 0.120 |
Why?
| | Retinal Pigments | 1 | 2014 | 5 | 0.120 |
Why?
| | Lens, Crystalline | 2 | 2016 | 96 | 0.120 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2016 | 162 | 0.120 |
Why?
| | Acid Phosphatase | 1 | 2014 | 17 | 0.120 |
Why?
| | Rhodamines | 1 | 2014 | 17 | 0.120 |
Why?
| | G2 Phase | 1 | 2014 | 31 | 0.120 |
Why?
| | Neoplasm Transplantation | 2 | 2019 | 230 | 0.120 |
Why?
| | Neoplasm Invasiveness | 1 | 2016 | 442 | 0.120 |
Why?
| | Diabetes Complications | 1 | 2016 | 212 | 0.120 |
Why?
| | Quinones | 1 | 2013 | 10 | 0.110 |
Why?
| | Transcription Factors | 1 | 2021 | 1531 | 0.110 |
Why?
| | Cataract | 1 | 2016 | 185 | 0.110 |
Why?
| | Retinal Diseases | 1 | 2014 | 76 | 0.110 |
Why?
| | Drug Stability | 1 | 2013 | 152 | 0.110 |
Why?
| | Endotoxins | 1 | 2014 | 205 | 0.110 |
Why?
| | Green Fluorescent Proteins | 2 | 2012 | 373 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1354 | 0.110 |
Why?
| | Genetic Variation | 1 | 2018 | 876 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2020 | 2563 | 0.110 |
Why?
| | Acitretin | 1 | 2012 | 3 | 0.100 |
Why?
| | Miconazole | 1 | 2012 | 4 | 0.100 |
Why?
| | Antiviral Agents | 1 | 2018 | 647 | 0.100 |
Why?
| | Isotretinoin | 1 | 2012 | 22 | 0.100 |
Why?
| | Hydrobromic Acid | 1 | 2012 | 1 | 0.100 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 91 | 0.100 |
Why?
| | Luciferases | 1 | 2012 | 142 | 0.100 |
Why?
| | Tissue Culture Techniques | 1 | 2012 | 66 | 0.100 |
Why?
| | Eye | 1 | 2012 | 101 | 0.100 |
Why?
| | Retina | 1 | 2014 | 263 | 0.100 |
Why?
| | Inhibitory Concentration 50 | 1 | 2011 | 75 | 0.100 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2012 | 165 | 0.100 |
Why?
| | Genes, Reporter | 1 | 2012 | 257 | 0.100 |
Why?
| | Software | 1 | 2015 | 538 | 0.100 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2012 | 138 | 0.100 |
Why?
| | Hyperglycemia | 1 | 2014 | 293 | 0.090 |
Why?
| | Oxazoles | 1 | 2011 | 29 | 0.090 |
Why?
| | Vimentin | 1 | 2011 | 58 | 0.090 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 851 | 0.090 |
Why?
| | Female | 8 | 2021 | 59617 | 0.090 |
Why?
| | In Vitro Techniques | 1 | 2011 | 1036 | 0.080 |
Why?
| | Inflammation Mediators | 1 | 2012 | 476 | 0.080 |
Why?
| | Lipopolysaccharides | 1 | 2012 | 817 | 0.080 |
Why?
| | Macrophages | 2 | 2014 | 1267 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2014 | 956 | 0.080 |
Why?
| | Oxidation-Reduction | 1 | 2012 | 926 | 0.080 |
Why?
| | Cells, Cultured | 4 | 2022 | 3896 | 0.080 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 151 | 0.080 |
Why?
| | Heat-Shock Response | 1 | 2008 | 46 | 0.070 |
Why?
| | Computer Simulation | 1 | 2012 | 881 | 0.070 |
Why?
| | Stereoisomerism | 1 | 2007 | 91 | 0.070 |
Why?
| | Hydrocarbons, Halogenated | 1 | 2007 | 5 | 0.070 |
Why?
| | Quinolines | 1 | 2008 | 129 | 0.070 |
Why?
| | Mycotoxins | 1 | 2006 | 3 | 0.070 |
Why?
| | Beauveria | 1 | 2006 | 2 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2020 | 4718 | 0.070 |
Why?
| | Protein Binding | 1 | 2012 | 1898 | 0.070 |
Why?
| | Pyrroles | 1 | 2007 | 181 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2008 | 214 | 0.070 |
Why?
| | Quinolones | 1 | 2007 | 97 | 0.070 |
Why?
| | Fungal Proteins | 1 | 2006 | 119 | 0.070 |
Why?
| | Solutions | 1 | 2006 | 148 | 0.060 |
Why?
| | Peptides, Cyclic | 1 | 2007 | 254 | 0.060 |
Why?
| | Catalysis | 1 | 2006 | 292 | 0.060 |
Why?
| | Imidazolidines | 2 | 2014 | 8 | 0.060 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2006 | 512 | 0.060 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 797 | 0.060 |
Why?
| | Melanoma, Experimental | 1 | 2005 | 89 | 0.060 |
Why?
| | Oxidative Stress | 2 | 2022 | 1085 | 0.050 |
Why?
| | Models, Chemical | 1 | 2005 | 250 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2022 | 25 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1558 | 0.050 |
Why?
| | Inflammation | 1 | 2012 | 2485 | 0.050 |
Why?
| | Oximes | 1 | 2021 | 19 | 0.050 |
Why?
| | Reactive Oxygen Species | 2 | 2014 | 536 | 0.050 |
Why?
| | Indazoles | 1 | 2021 | 58 | 0.050 |
Why?
| | Mass Spectrometry | 2 | 2018 | 634 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 317 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2021 | 271 | 0.040 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2020 | 82 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 276 | 0.040 |
Why?
| | Azacitidine | 1 | 2020 | 129 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 313 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 697 | 0.040 |
Why?
| | Depsides | 1 | 2018 | 1 | 0.040 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2020 | 236 | 0.040 |
Why?
| | Proteolysis | 1 | 2019 | 143 | 0.040 |
Why?
| | Cell Line | 2 | 2018 | 2645 | 0.040 |
Why?
| | Vero Cells | 1 | 2018 | 63 | 0.040 |
Why?
| | RNA Caps | 1 | 2018 | 31 | 0.040 |
Why?
| | Salicylates | 1 | 2018 | 30 | 0.040 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 33 | 0.040 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 37 | 0.040 |
Why?
| | Cricetinae | 1 | 2018 | 259 | 0.040 |
Why?
| | Lactones | 1 | 2018 | 54 | 0.040 |
Why?
| | Fluorescence | 1 | 2018 | 148 | 0.040 |
Why?
| | Anthocyanins | 1 | 2018 | 29 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2018 | 243 | 0.040 |
Why?
| | Stem Cells | 1 | 2021 | 546 | 0.040 |
Why?
| | Gene Frequency | 1 | 2018 | 483 | 0.030 |
Why?
| | Aldo-Keto Reductases | 1 | 2016 | 1 | 0.030 |
Why?
| | Protein Processing, Post-Translational | 1 | 2019 | 399 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2018 | 348 | 0.030 |
Why?
| | Colchicine | 1 | 2015 | 24 | 0.030 |
Why?
| | Tubulin Modulators | 1 | 2015 | 9 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 282 | 0.030 |
Why?
| | Treatment Outcome | 1 | 2009 | 9123 | 0.030 |
Why?
| | Molecular Docking Simulation | 1 | 2015 | 102 | 0.030 |
Why?
| | Genetic Testing | 1 | 2018 | 380 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 788 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1700 | 0.030 |
Why?
| | Tubulin | 1 | 2015 | 123 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 55 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1169 | 0.030 |
Why?
| | Computational Biology | 1 | 2018 | 533 | 0.030 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2014 | 119 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2017 | 436 | 0.030 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2012 | 23 | 0.030 |
Why?
| | Diabetic Retinopathy | 1 | 2014 | 149 | 0.030 |
Why?
| | MCF-7 Cells | 1 | 2012 | 105 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 262 | 0.020 |
Why?
| | Uveitis | 1 | 2012 | 115 | 0.020 |
Why?
| | Blotting, Western | 1 | 2014 | 1149 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2014 | 1153 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2014 | 1229 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2016 | 1955 | 0.020 |
Why?
| | Algorithms | 1 | 2018 | 1489 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3335 | 0.020 |
Why?
| | Cell Movement | 1 | 2014 | 866 | 0.020 |
Why?
| | Glucose | 1 | 2014 | 900 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2012 | 1084 | 0.020 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 2008 | 43 | 0.020 |
Why?
| | Marine Biology | 1 | 2007 | 2 | 0.020 |
Why?
| | Toxicity Tests, Acute | 1 | 2007 | 9 | 0.020 |
Why?
| | Fiji | 1 | 2007 | 3 | 0.020 |
Why?
| | Antibiotics, Antitubercular | 1 | 2006 | 35 | 0.020 |
Why?
| | Cytokines | 1 | 2014 | 1843 | 0.020 |
Why?
| | Spectrum Analysis | 1 | 2006 | 81 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2008 | 482 | 0.020 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 1 | 2007 | 238 | 0.020 |
Why?
| | Binding Sites | 1 | 2008 | 1173 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2014 | 3545 | 0.010 |
Why?
| | Signal Transduction | 1 | 2017 | 4525 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 268 | 0.010 |
Why?
| | Amino Acids | 1 | 2006 | 451 | 0.010 |
Why?
| | Aged | 1 | 2019 | 19122 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 26830 | 0.010 |
Why?
| | Male | 1 | 2012 | 55735 | 0.000 |
Why?
|
|
LaBarbera's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|